Gufic Biosciences Limited: Acquisition
Gufic Biosciences, a BSE/NSE-listed pharmaceutical company, notified the exchange of an acquisition on 14 August 2026. The NSE archive filing provides formal notice but no detailed terms, consideration, target name, or completion date are visible in the headline extract. The full acquisition structure, regulatory approvals (DCGI, FIPB/DPIIT if applicable, CCI if turnover thresholds crossed) and closing conditions will require review of the complete disclosure document.
Why it mattersPharma M&A in India requires pre-closing DCGI/CDSCO approval if the target holds manufacturing or regulatory licenses; counsel must sequence approvals with stock exchange disclosure timing and foreign-exchange compliance if cross-border.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Filings Archive · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026